The choice of pharmacotherapy should take into consideration the individual characteristics of each patient and the advantages of each anti-obesity medication, since some may be more beneficial than others; for example, GLP-1 receptor agonists such as liraglutide and semaglutide confer a greater improvement in glycemia, and thus they are expected to be the primary medication class for obesity management in patients with pre-diabetes [4,56]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.